Clinic
Crimson Care LLC
Crimson Care LLC was paid $1.50M by Medicaid between Feb 2018 and Dec 2024, across 46 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 39% of everything it billed.
33Billing provider infoCRIMSON CARE LLC
TUSCALOOSA, AL 35405
TUSCALOOSA, AL 35405
33aNPI1437668639assigned 09/20/2017
33bProvider typeUrgent Care Clinic/Center
28Total paid$1.50M
24GClaims65,783
24DCodes billed46
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Alabama
Rank by total paid#4 of 59
Median peer was paid$77K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 543 | $10K | |
| 2019 | 3,345 | $64K | |
| 2020 | 6,813 | $169K | |
| 2021 | 11,576 | $221K | |
| 2022 | 19,095 | $403K | |
| 2023 | 13,460 | $440K | |
| 2024incomplete | 10,951 | $195K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 39% | 7,677 | 6,454 | $582K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 4,338 | 3,518 | $217K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 14% | 1,829 | 1,591 | $210K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 8.3% | 1,607 | 1,411 | $125K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.9% | 9,763 | 4,204 | $88K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.8% | 3,625 | 3,383 | $87K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.7% | 2,215 | 1,646 | $41K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 3,201 | 2,884 | $36K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 3,559 | 3,016 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.9% | 2,706 | 2,293 | $29K |
| 87428 | 1.3% | 458 | 431 | $19K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 816 | 687 | $12K |
34 more codes
| 87807 | <1% | 918 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 300 | $7K |
| 81002 | <1% | 1,176 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,368 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 50 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 219 | $2K |
| 81025 | <1% | 655 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 661 | $731.97 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,855 | $713.72 |
| 81003 | <1% | 99 | $87.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 39 | $64.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 17 | $19.84 |
| 1170F | <1% | 2,701 | $1.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 104 | $0.09 |
| 1159F | 0% | 2,506 | $0.00 | |
| 1494F | 0% | 1,095 | $0.00 | |
| 3078F | 0% | 888 | $0.00 | |
| 1160F | 0% | 2,505 | $0.00 | |
| 3077F | 0% | 304 | $0.00 | |
| G8421 | Bmi not documented and no reason is given | 0% | 16 | $0.00 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | 0% | 40 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 146 | $0.00 |
| 3008F | 0% | 3,206 | $0.00 | |
| 2010F | 0% | 243 | $0.00 | |
| 3079F | 0% | 318 | $0.00 | |
| 3074F | 0% | 1,029 | $0.00 | |
| 1125F | 0% | 13 | $0.00 | |
| 2001F | 0% | 385 | $0.00 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 358 | $0.00 |
| 3075F | 0% | 196 | $0.00 | |
| 3080F | 0% | 212 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 65 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 209 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 93 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERAMSETTY, SASANK (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Crimson Urgent Care, LLC | Tuscaloosa, AL | $1.45M |
| First Kids | Tuscaloosa, AL | $1.35M |
| First Care LLC | Tuscaloosa, AL | $812K |
| Alabama Family Medical Center, LLC | Tuscaloosa, AL | $168K |
| Crimson Care North | Northport, AL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.